Patents by Inventor Katalin Prokai
Katalin Prokai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7572781Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).Type: GrantFiled: February 15, 2007Date of Patent: August 11, 2009Assignees: University of Florida, University of North Texas Health Science CenterInventors: Laszlo Prokai, Katalin Prokai, James Simpkins, Neeraj Agarwal
-
Patent number: 7534779Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transcorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).Type: GrantFiled: August 14, 2007Date of Patent: May 19, 2009Assignees: University of Florida, University of North Texas Health Science CenterInventors: Laszlo Prokai, Katalin Prokai
-
Publication number: 20080119446Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transcorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).Type: ApplicationFiled: August 14, 2007Publication date: May 22, 2008Inventors: Laszlo Prokai, Katalin Prokai
-
Patent number: 7300926Abstract: The present invention relates to novel estrogen-related steroidal quinols and their use as drugs for estrogen replacement therapy. The quinols of the present invention provide improved physicochemical properties, increased bioavailability, and improved distribution into tissues, bone, in the cardiovascular system, and in the CNS (central nervous system) with only a slight estrogenic action or no estrogenic action in the uterus. The compounds are suitable for the production of pharmaceutical agents for use in numerous indications (for example, estrogen replacement therapy, prevention and treatment of osteoporosis).Type: GrantFiled: September 17, 2003Date of Patent: November 27, 2007Assignees: University of Florida Research Foundation, Inc., University of North Texas Health Science Center at Fort WorthInventors: Laszlo Prokai, Katalin Prokai, James Simpkins
-
Publication number: 20070213310Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).Type: ApplicationFiled: March 5, 2007Publication date: September 13, 2007Inventors: Laszlo Prokai, Katalin Prokai
-
Publication number: 20070155711Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcomeal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocomeal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).Type: ApplicationFiled: February 15, 2007Publication date: July 5, 2007Inventors: Laszlo Prokai, Katalin Prokai, James Simpkins, Neeraj Agarwal
-
Patent number: 7186707Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).Type: GrantFiled: December 9, 2003Date of Patent: March 6, 2007Assignees: University of Florida, University of North Texas Health Science CenterInventors: Laszlo Prokai, Katalin Prokai, James Simpkins, Neeraj Agarwal
-
Patent number: 7026306Abstract: The present invention relates to novel estrogen-related steroidal quinols and their use as prodrugs for phenolic estrogens and estrogen analogs. The quinols of the present invention provide improved physicochemical properties, increased bioavailability, and improved distribution into tissues and penetration across the blood-brain barrier when compared to phenolic estrogens and estrogen analogs.Type: GrantFiled: April 1, 2003Date of Patent: April 11, 2006Assignees: University of Florida Research Foundation, Inc., University of North Texas Health Science CenterInventors: Laszlo Prokai, Katalin Prokai, James Simpkins
-
Publication number: 20040171596Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).Type: ApplicationFiled: December 9, 2003Publication date: September 2, 2004Inventors: Laszlo Prokai, Katalin Prokai, James Simpkins, Neeraj Agarwal
-
Publication number: 20040138190Abstract: The present invention relates to novel estrogen-related steroidal quinols and their use as drugs for estrogen replacement therapy. The quinols of the present invention provide improved physicochemical properties, increased bioavailability, and improved distribution into tissues, bone, in the cardiovascular system, and in the CNS (central nervous system) with only a slight estrogenic action or no estrogenic action in the uterus. The compounds are suitable for the production of pharmaceutical agents for use in numerous indications (for example, estrogen replacement therapy, prevention and treatment of osteoporosis).Type: ApplicationFiled: September 17, 2003Publication date: July 15, 2004Inventors: Laszlo Prokai, Katalin Prokai, James Simpkins
-
Publication number: 20030229060Abstract: The present invention relates to novel estrogen-related steroidal quinols and their use as prodrugs for phenolic estrogens and estrogen analogs. The quinols of the present invention provide improved physicochemical properties, increased bioavailability, and improved distribution into tissues and penetration across the blood-brain barrier when compared to phenolic estrogens and estrogen analogs.Type: ApplicationFiled: April 1, 2003Publication date: December 11, 2003Inventors: Laszlo Prokai, Katalin Prokai, James Simpkins
-
Patent number: 5741802Abstract: The invention concerns novel anabaseine-related compounds that are useful in treating certain degenerative neural diseases such as Alzheimer's and Parkinson's which apparently involve decreased function of cerebral cortical nicotinic receptors. The compounds showed activity in both in vitro and in active and passive active avoidance studies in animal models. An exemplary active compound is a 3-substituted 2,4-dimethoxy-benzylidene anabaseine.Type: GrantFiled: January 5, 1996Date of Patent: April 21, 1998Assignee: University of FloridaInventors: William R. Kem, John A. Zoltewicz, Edwin M. Meyer, Katalin Prokai-Tatrai